Neal Eylar
Optometrist · Overland Park, KSNPI 1609072586
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$771
- Oyster Point Pharma, Inc.$365
- Bausch & Lomb, A Division Of Bausch Health US, LLC$348
- Bausch & Lomb Americas Inc.$318
- Sun Pharmaceutical Industries Inc.$314
- Glaukos Corporation$308
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,697100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 31 | $771 |
| Oyster Point Pharma, Inc. | 17 | $365 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $348 |
| Bausch & Lomb Americas Inc. | 17 | $318 |
| Sun Pharmaceutical Industries Inc. | 14 | $314 |
| Glaukos Corporation | 7 | $308 |
| Johnson & Johnson Vision Care, Inc. | 16 | $306 |
| Dompe US, Inc. | 8 | $275 |
| Coopervision Inc. | 11 | $214 |
| Mallinckrodt Hospital Products Inc. | 10 | $202 |
| Astellas Pharma US Inc | 2 | $157 |
| Harrow Eye, LLC | 4 | $103 |
| Genentech USA, Inc. | 4 | $103 |
| Sandoz | 3 | $97 |
| Biotissue Holdings Inc. | 5 | $93 |
| Rxsight Inc | 1 | $92 |
| Novartis | 6 | $89 |
| Tarsus Pharmaceuticals, Inc. | 3 | $82 |
| Coherus Oncology, Inc. | 2 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Apellis Pharmaceuticals, Inc. | 2 | $51 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Shire North American Group Inc | 2 | $42 |
| AbbVie(2 entities) | 2 | $31 |
| Menicon America Inc | 1 | $27 |
| Alcon Research LLC | 2 | $26 |
| Alimera Sciences, Inc. | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Thea Pharma Inc. | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$150
- TRYPTYR$119
- KXL System$112
- Photrexa$112
- Oxervate$102
How this compares
$4,697 in reported general payments places this provider in the 95th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $11,254 |
| LumiganBimatoprost | 22 | $9,934 |
| Prednisolone Acetate | 126 | $3,721 |
| Timolol Maleate | 44 | $1,465 |
| Latanoprost | 77 | $972 |
| Doxycycline Hyclate | 33 | $756 |
| Acetazolamide | 14 | $664 |
| Brimonidine Tartrate | 18 | $562 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 35 | $442 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $195 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $31 | $21,18834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 optometrist providers in Kansas.
Other optometrist in Overland Park
- Vincent PennipedeOverland Park$16K
- Mark SiefkesOverland Park$11K
- Katherine PainterOverland Park$7K
- Jared JaynesOverland Park$5K
- Anthony BrandOverland Park$5K
- Jay BurlingameOverland Park$5K
- Dawn BircherOverland Park$4K
- Liron BittanOverland Park$4K
- L BeslerOverland Park$4K
- Buffie MockOverland Park$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.